Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 23, 2004
Application Includes Extensive Preclinical and Clinical Data on 6R-BH4BioMarin Pharmaceutical Inc. announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for Phenoptin(TM), BioMarin's proprietary...
-
Aug 12, 2004
BioMarin Pharmaceutical Inc. announced today that Fredric D. Price has resigned as Chairman and Chief Executive Officer (CEO) of the company in order to relocate back to the East Coast. Pierre...
-
Aug 9, 2004Second Quarter GAAP Net Loss of $0.86 Per Share and Pro Forma Adjusted Net Loss of $0.28 Per Share
BioMarin Pharmaceutical Inc. today announced financial results for the second quarter of the fiscal year 2004. The company incurred a GAAP net loss of $55.6 million ($0.86 per share) for the...
-
Jul 19, 2004Study Demonstrates Substantial Reduction in Phenylalanine Levels in PKU Patients
BioMarin Pharmaceutical Inc. announced positive results from a pilot clinical study of 6R-BH4 in 20 patients with phenylketonuria (PKU). 6R-BH4 is the active agent in Phenoptin(TM), an...
-
Jun 2, 2004Aryplase Demonstrates Statistically Significant Benefit in Primary Endpoint
BioMarin Pharmaceutical Inc. today announced positive results from its Phase 3 clinical trial of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...